
|Videos|April 14, 2021
A 63-Year-Old Woman With Recurrent Ovarian Cancer
Erin Crane, MD, reviews the case of a 63-year-old woman with recurrent ovarian cancer and discusses treatment options, the Phase 3 NOVA trial, and the future of ovarian cancer treatment.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5





































